While the concept of correcting the expression imbalance of cadherin genes presents an appealing therapeutic strategy, it is important to acknowledge that currently, no clinically approved treatments specifically target CDH1, CDH2, or CDH3 in NSCLC. This evidence concerns the gene CDH3 and non-small cell lung carcinoma.